A RANDOMIZED PHASE III STUDY OF LOW-DOCETAXEL OXALIPLATIN, CAPECITABINE (LOW-TOX) VS EPIRUBICIN, OXALIPLATIN AND CAPECITABINE (EOX) IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER